top pharma analyst and investor on timing and effectiveness of a potential covid vaccine
Published 4 years ago • 3.9K plays • Length 6:30Download video MP4
Download video MP3
Similar videos
-
6:25
state of vaccine development and what it means for pharma companies
-
59:52
how moderna and pfizer-biontech developed vaccines in record time
-
9:54
jim cramer breaks down stocks of companies in the race to develop a coronavirus vaccine
-
4:51
the effectiveness of covid-19 vaccines against variants
-
2:54
health-care analyst explains how big pharma is approaching coronavirus crisis
-
5:26
trade it or fade it: the week's big biotech moves
-
55:57
watch cnbc's full interview with legendary short seller jim chanos
-
1:01:48
why pharmaceuticals are so complicated in the u.s. | cnbc marathon
-
4:49
the stocks with upside amid covid-19 vaccine rollout: bank of america's geoff meacham
-
17:03
what is an mrna coronavirus vaccine?
-
5:31
why this analyst likes pfizer and thinks it can step in if necessary for j&j
-
1:54
covid stocks in biotech and pharma see some of the biggest selloffs
-
4:52
chartmaster: big move in vaccine names
-
3:23
jim cramer on race to develop a vaccine, and reopening u.s. economy from covid-19 lockdowns
-
3:33
coronavirus: vanda pharmaceutical ceo on vaccine
-
2:49
pfizer ceo on covid-19 vaccine efficacy: 'it is a great day for humanity'
-
3:30
how moderna became the frontrunner for coronavirus vaccine
-
2:10
pfizer: full vaccine results indicate its covid-19 vaccine is 95% effective
-
3:29
pfizer's covid-19 vaccine appears to stop variants found in u.k., south africa
-
5:20
j&j says its one-shot covid-19 vaccine is 72% effective in the u.s.
-
3:17
oxford/astrazeneca covid-19 vaccine can be up to 90% effective
-
13:11
why the us covid vaccine rollout is going slower than planned: cnbc after hours